Breaking Innovation Paralysis
Why Canada keeps losing the cures, capital, and companies it builds.
And what it would take to stop.
World Class Innovation. Last Place Access.
Canada ranks last in the G7 for timely access to new medicines. Startups built here routinely scale somewhere else. Promising technologies sit validated and unused for years. This isn't a funding problem or a talent problem — it's a pattern, and it repeats at every level of the system. Canada doesn't suffer from an innovation deficit. It suffers from an institutional courage gap.
Where The Thesis Lives
Three things are underway: a book — Innovation Paralysis: Why Canada Keeps Losing the Cures, Capital, and Companies It Builds — currently in research. A podcast, launching soon, in conversation with the founders, clinicians, regulators, and policymakers living inside this problem. And a small number of speaking and advisory conversations, taken on selectively where the thesis is genuinely useful.
Three Mechanisms. One Pattern.
The same three forces repeat at every scale — from an individual who won't click a link to a cabinet that passes four surveillance bills without owning their cumulative effect. The mechanisms don't change. But as the system scales, the consequences compound. What costs one person thirty seconds costs a country its cures.
Inertia
The default to status quo when there's no activation energy pulling anyone toward action.
Diffusion of Responsibility
When everyone assumes someone else owns the problem, so no one does.
Avoiding whichever action carries the most visible blame — whether that means doing nothing, or overreacting.
Risk Aversion
Moving Beyond the Generic Playbook
Most writing on innovation culture is either purely academic or generic corporate advice with no specific stakes. This work is different on four counts worth naming directly.
It's Canada-specific. Not a generalized theory borrowed from the US or the UK, but an argument built from the ground up about where this particular country's health innovation ecosystem actually breaks down.
It's anchored in life sciences and healthcare, where the cost of paralysis isn't measured in lost revenue alone — it's measured in how long patients wait for treatments that already exist.
It treats the whole system, not a single organization. Most innovation consulting is built to fix one company's internal culture. This work treats the incubator, the funder, the regulator, and the hospital as one interconnected system — the same macro, systems-level view a policymaker needs, not just a leadership team.
And it's grounded in both lived experience and formal behavioral science. Three decades inside every layer of this ecosystem — as a clinician, a pharmaceutical executive, and a bootstrapped founder — alongside a Positive Psychology specialization from the University of Pennsylvania, which is precisely the science of moving human systems from merely surviving to genuinely flourishing.
Who This Is For
Founders & Innovators
You've built something real, and it's still sitting in a pilot or waiting on a procurement committee. This framework gives you precise language for what you're actually hitting — not "the system is slow" but the specific mechanism stalling your specific handoff.
Use it to diagnose where commercialization is stuck, sharpen your pitch to risk-averse buyers, and find the outside voice that gives your internal champion the cover to move.
Policy Makers & Regulators
Life Science and Healthcare Leaders
Patients & Advocates
You didn't design this system to produce paralysis — you designed it to produce safety and accountability. But good intentions embedded in fragmented institutions produce stalled outcomes regardless. This framework offers a systems-level account of where the gap between intent and outcome actually originates.
Use it to pressure-test cumulative policy effects, identify invisible accountability gaps, and build the evidentiary case for reform that goes beyond anecdote.
You already know your organization is risk-averse. The problem is that the incentive architecture rewards caution at every individual decision point even when the aggregate outcome is clearly costing you. This framework maps exactly where your friction sits and offers practical interventions that work within your existing compliance architecture.
Use it to prepare leadership teams for complex transitions, accelerate adoption, and give internal champions structured cover to move.
The treatments that could help exist. In many cases they've passed trials, cleared regulators, and been validated. The gap between that and actual access isn't a science problem — it's a systems problem.
Use this framework to understand why the pipeline moves slowly, hold institutions accountable at the handoffs where access gets lost, and make the human cost of paralysis visible in policy conversations where it's too often reduced to timelines and budget cycles.
